Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity.
OBJECTIVE
We sought to review efficacy and toxicity of an 8-day methotrexate (MTX) regimen in the treatment of patients with low-risk gestational trophoblastic neoplasia (GTN) from the French Trophoblastic Disease Reference Center.


METHODS
Between 1999 and 2006, 142 low-risk GTNs were diagnosed according to International Federation of Gynecology and Obstetrics (FIGO) criteria for GTN and to the FIGO scoring system. We report their characteristics, remission/resistance/recurrence rates, and treatment toxicity.


RESULTS
The 8-day MTX regimen achieved a 77.5% remission rate. All patients but 1 (99.9%) achieved remission and remained disease free until the time of analysis. Severe (grade 3 or 4) blood/bone marrow toxicity and metabolic/laboratory toxicity was noted in 4.2% of cases, of which 2 (1.4%) were grade 4.


CONCLUSIONS
For patients with GTN diagnosed according to FIGO criteria and considered low risk according to the FIGO scoring system, an 8-day MTX regimen is an adequate treatment associating a high rate of remission to a low rate of toxicity.
Chalouhi
Gihad Elias
GE
Université de Lyon, F-69622, Lyon, France.
Golfier
François
F
Soignon
Pauline
P
Massardier
Jerome
J
Guastalla
Jean-Paul
JP
Trillet-Lenoir
Veronique
V
Schott
Anne-Marie
AM
Raudrant
Daniel
D
D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000145:classification / Q000188:drug therapy*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged; D011247:Pregnancy; D012307:Risk Factors; D055815:Young Adult
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate